Chapa-González Christian, López Karina, Lomelí Kimberly Michelle, Roacho-Pérez Jorge Alberto, Stevens Jazmín Cristina
Grupo de Investigación de Nanomedicina-UACJ, Instituto de Ingeniería y Tecnología, Universidad Autónoma de Ciudad Juárez, Ciudad Juárez 32310, Mexico.
Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
Life (Basel). 2022 Feb 22;12(3):327. doi: 10.3390/life12030327.
Pancreatic cancer has one of the highest mortality rates among cancers, and a combination of nab-paclitaxel with gemcitabine remains the cornerstone of first-line therapy. However, major advances are required to achieve improvements in patient outcomes. For this reason, several research groups have proposed supplementing treatment with other therapeutic agents. Ongoing studies are being conducted to find the optimal treatment in a first-line setting. In this work, we used a search strategy to compare studies on the efficacy and safety of nab-paclitaxel with gemcitabine in combination with other therapeutic agents based on the criteria of the Preferred Reporting Items for Systematic Reviews. We found seven studies in different clinical phases that met the inclusion criteria. The seven therapeutic agents were ibrutinib, necuparanib, tarextumab, apatorsen, cisplatin, enzalutamide, and momelotinib. Although these therapeutic agents have different mechanisms of action, and molecular biology studies are still needed, the present review was aimed to answer the following question: which formulations of the nab-paclitaxel/gemcitabine regimen in combination with other therapeutic agents are safest for patients with previously untreated metastatic pancreas ductal adenocarcinoma? The triple regimen is emerging as the first-line option for patients with pancreatic cancer, albeit with some limitations. Thus, further studies of this regimen are recommended.
胰腺癌是癌症中死亡率最高的疾病之一，纳米白蛋白结合型紫杉醇与吉西他滨联合使用仍然是一线治疗的基石。然而，要改善患者预后还需要取得重大进展。因此，几个研究小组建议用其他治疗药物补充治疗。目前正在进行研究以寻找一线治疗中的最佳治疗方案。在这项工作中，我们采用了一种检索策略，根据系统评价的首选报告项目标准，比较纳米白蛋白结合型紫杉醇与吉西他滨联合其他治疗药物的疗效和安全性的研究。我们发现了七项处于不同临床阶段且符合纳入标准的研究。这七种治疗药物分别是伊布替尼、尼库帕尼、他雷妥单抗、阿帕托森、顺铂、恩杂鲁胺和莫洛替尼。尽管这些治疗药物的作用机制不同，仍需要进行分子生物学研究，但本综述旨在回答以下问题：对于先前未接受治疗的转移性胰腺导管腺癌患者，纳米白蛋白结合型紫杉醇/吉西他滨方案与其他治疗药物联合使用的哪种制剂最安全？三联方案正在成为胰腺癌患者的一线选择，尽管存在一些局限性。因此，建议对该方案进行进一步研究。
